NovoCure (NVCR) Non-Current Deffered Revenue (2014 - 2023)

NovoCure (NVCR) has reported Non-Current Deffered Revenue for 10 consecutive years, with $807000.0 the latest figure, recorded in Q2 2023.

• Quarterly Non-Current Deffered Revenue fell 82.23% year-over-year to $807000.0 in Q2 2023, while the trailing twelve-month figure through Jun 2023 was $807000.0 (down 82.23% YoY) and the FY2022 annual result came in at $2.9 million, down 55.57% from the prior year.
• Non-Current Deffered Revenue declined to $807000.0 in Q2 2023 per NVCR's latest filing, from $1.8 million in the prior quarter.
• Over the last five years, Non-Current Deffered Revenue for NVCR reached as high as $12.1 million in Q4 2020 and fell as low as $807000.0 in Q2 2023.
• A 5-year average of $7.0 million and a median of $7.9 million in 2019 frame the typical range for Non-Current Deffered Revenue.
• Annual changes were most pronounced in 2020 — Non-Current Deffered Revenue surged 55.49% — and 2023, when it sank 82.23%.
• Year by year, Non-Current Deffered Revenue stood at $7.8 million in 2019, then jumped by 55.49% to $12.1 million in 2020, then sank by 46.64% to $6.5 million in 2021, then tumbled by 55.57% to $2.9 million in 2022, then tumbled by 71.96% to $807000.0 in 2023.
• According to Business Quant data, Non-Current Deffered Revenue over the past three periods registered $807000.0, $1.8 million, and $2.9 million for Q2 2023, Q1 2023, and Q4 2022 respectively.